pyruvic acid has been researched along with Heart Failure in 34 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
Excerpt | Relevance | Reference |
---|---|---|
"The purpose of present study was to investigate the effect of metabolic substrate pyruvate and beta-adrenergic agonist isoproterenol and combination of these agents on the force- and relaxation-frequency relationship in human heart failure." | 7.73 | The force-frequency relationship in human heart failure: effect of pyruvate and isoproterenol. ( Gendviliene, V; Gurskaite, H; Martisiene, I; Zablockaite, D, 2005) |
"The purpose of present study was to investigate the effect of metabolic substrate pyruvate and beta-adrenergic agonist isoproterenol and combination of these agents on the force- and relaxation-frequency relationship in human heart failure." | 3.73 | The force-frequency relationship in human heart failure: effect of pyruvate and isoproterenol. ( Gendviliene, V; Gurskaite, H; Martisiene, I; Zablockaite, D, 2005) |
"Decreased MPC expression in several cancers limits the mitochondrial oxidation of pyruvate and contributes to lactate accumulation in the cytosol, highlighting its role as a contributing, causal mediator of the Warburg effect." | 2.72 | Heart failure-emerging roles for the mitochondrial pyruvate carrier. ( Eaton, P; Fernandez-Caggiano, M, 2021) |
"Cardiac hypertrophy was also evident by a 49% increase in whole cell capacitance of isolated left ventricular myocytes (P < 0." | 1.30 | Altered K+ current of ventricular myocytes in rats with chronic myocardial infarction. ( Patel, KP; Rozanski, GJ; Xu, Z; Zhang, K, 1998) |
"The clinical sings of cardiac failure are unequivocal." | 1.26 | [Congestive heart failure due to chronic alcoholism (author's transl)]. ( Tatibouet, L; Tatibouet, MH, 1982) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 11 (32.35) | 18.7374 |
1990's | 5 (14.71) | 18.2507 |
2000's | 7 (20.59) | 29.6817 |
2010's | 6 (17.65) | 24.3611 |
2020's | 5 (14.71) | 2.80 |
Authors | Studies |
---|---|
Bøgh, N | 1 |
Hansen, ESS | 1 |
Omann, C | 1 |
Lindhardt, J | 1 |
Nielsen, PM | 1 |
Stephenson, RS | 1 |
Laustsen, C | 1 |
Hjortdal, VE | 1 |
Agger, P | 1 |
Fernandez-Caggiano, M | 2 |
Kamynina, A | 1 |
Francois, AA | 1 |
Prysyazhna, O | 1 |
Eykyn, TR | 1 |
Krasemann, S | 1 |
Crespo-Leiro, MG | 1 |
Vieites, MG | 1 |
Bianchi, K | 1 |
Morales, V | 1 |
Domenech, N | 1 |
Eaton, P | 2 |
McCommis, KS | 1 |
Kovacs, A | 1 |
Weinheimer, CJ | 1 |
Shew, TM | 1 |
Koves, TR | 1 |
Ilkayeva, OR | 1 |
Kamm, DR | 1 |
Pyles, KD | 1 |
King, MT | 1 |
Veech, RL | 1 |
DeBosch, BJ | 1 |
Muoio, DM | 1 |
Gross, RW | 1 |
Finck, BN | 1 |
Cluntun, AA | 1 |
Badolia, R | 1 |
Lettlova, S | 1 |
Parnell, KM | 1 |
Shankar, TS | 1 |
Diakos, NA | 1 |
Olson, KA | 1 |
Taleb, I | 1 |
Tatum, SM | 1 |
Berg, JA | 1 |
Cunningham, CN | 1 |
Van Ry, T | 1 |
Bott, AJ | 1 |
Krokidi, AT | 1 |
Fogarty, S | 1 |
Skedros, S | 1 |
Swiatek, WI | 1 |
Yu, X | 1 |
Luo, B | 1 |
Merx, S | 1 |
Navankasattusas, S | 1 |
Cox, JE | 1 |
Ducker, GS | 1 |
Holland, WL | 1 |
McKellar, SH | 1 |
Rutter, J | 1 |
Drakos, SG | 1 |
Turer, A | 1 |
Altamirano, F | 1 |
Schiattarella, GG | 1 |
May, H | 1 |
Gillette, TG | 1 |
Malloy, CR | 1 |
Merritt, ME | 1 |
Zheng, MQ | 1 |
Li, X | 2 |
Tang, K | 2 |
Sharma, NM | 1 |
Wyatt, TA | 1 |
Patel, KP | 2 |
Gao, L | 1 |
Bidasee, KR | 1 |
Rozanski, GJ | 3 |
Xie, B | 1 |
Li, S | 1 |
Obrzut, S | 1 |
Tiongson, J | 1 |
Jamshidi, N | 1 |
Phan, HM | 1 |
Hoh, C | 1 |
Birgersdotter-Green, U | 1 |
Schillinger, W | 1 |
Hünlich, M | 2 |
Sossalla, S | 1 |
Hermann, HP | 5 |
Hasenfuss, G | 5 |
Schroeder, MA | 1 |
Lau, AZ | 1 |
Chen, AP | 1 |
Gu, Y | 1 |
Nagendran, J | 1 |
Barry, J | 1 |
Hu, X | 1 |
Dyck, JR | 1 |
Tyler, DJ | 1 |
Clarke, K | 1 |
Connelly, KA | 1 |
Wright, GA | 1 |
Cunningham, CH | 1 |
Westenbrink, BD | 1 |
Dorn, GW | 1 |
KLEEBERG, J | 1 |
GITELSON, S | 1 |
ANTALOCZY, Z | 2 |
BRETAN, M | 2 |
LOVEI, E | 2 |
GREIF, S | 1 |
HOCHEGGER, M | 1 |
AL BERMANI, MA | 1 |
GAVOSTO, F | 1 |
BUFFA, F | 1 |
CHIARLE, S | 1 |
SOLERIO, F | 1 |
BENDA, L | 1 |
DONEFF, D | 1 |
MOSER, K | 1 |
KARDASZEWICZ, S | 1 |
MASNY, N | 1 |
POPESCU, I | 1 |
ZAMFIRESCU-GHEORGHIU, M | 1 |
DOBREANUENESCU, V | 1 |
CIOBANU, F | 1 |
HARNAGEA, P | 1 |
BOZHKO, AP | 1 |
Arp, J | 1 |
Pieske, B | 4 |
Kögler, H | 1 |
Baron, S | 1 |
Janssen, PM | 3 |
Martisiene, I | 1 |
Gendviliene, V | 1 |
Zablockaite, D | 1 |
Gurskaite, H | 1 |
Tatibouet, L | 1 |
Tatibouet, MH | 1 |
Denisiuk, VI | 1 |
Alekseeva, OP | 1 |
Komarova, LG | 1 |
Sezai, A | 1 |
Shiono, M | 1 |
Orime, Y | 1 |
Nakata, K | 1 |
Hata, M | 1 |
Yamada, H | 1 |
Iida, M | 1 |
Kashiwazaki, S | 1 |
Kinishita, J | 1 |
Nemoto, M | 1 |
Koujima, T | 1 |
Sezai, Y | 1 |
Saitoh, T | 1 |
Xu, Z | 1 |
Zhang, K | 1 |
Schwarzmüller, E | 1 |
Keul, J | 1 |
Just, H | 1 |
Zeitz, O | 2 |
Lehnart, SE | 1 |
Keweloh, B | 1 |
Datz, N | 1 |
Lopaschuk, GD | 1 |
Rebeyka, IM | 1 |
Allard, MF | 1 |
Maier, LS | 2 |
Lüers, C | 1 |
Braunhälter, J | 1 |
Horn, W | 1 |
Weichert, S | 1 |
Wasserman, K | 1 |
Beaver, WL | 1 |
Whipp, BJ | 1 |
Whitmer, JT | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation[NCT00604331] | Phase 2 | 8 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
Hyperpolarized MRSI in Ischemic Heart Disease: Metabolic Profiling of the Myocardium[NCT06054516] | 15 participants (Anticipated) | Observational | 2023-10-13 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 reviews available for pyruvic acid and Heart Failure
Article | Year |
---|---|
Heart failure-emerging roles for the mitochondrial pyruvate carrier.
Topics: Animals; Heart Failure; Humans; Mice; Mitochondria; Mitochondrial Membrane Transport Proteins; Monoc | 2021 |
Gas exchange theory and the lactic acidosis (anaerobic) threshold.
Topics: Acidosis, Lactic; Anaerobic Threshold; Heart Failure; Humans; Models, Cardiovascular; Oxygen Consump | 1990 |
1 trial available for pyruvic acid and Heart Failure
Article | Year |
---|---|
Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study.
Topics: Cardiac Catheterization; Cardiomyopathy, Dilated; Coronary Vessels; Female; Heart Failure; Hemodynam | 1999 |
31 other studies available for pyruvic acid and Heart Failure
Article | Year |
---|---|
Increasing carbohydrate oxidation improves contractile reserves and prevents hypertrophy in porcine right heart failure.
Topics: Animals; Carbohydrate Metabolism; Carbohydrates; Female; Heart; Heart Failure; Heart Ventricles; Hum | 2020 |
Mitochondrial pyruvate carrier abundance mediates pathological cardiac hypertrophy.
Topics: Angiotensin II; Animals; Anion Transport Proteins; Cardiomegaly; Cell Proliferation; Citric Acid Cyc | 2020 |
Nutritional modulation of heart failure in mitochondrial pyruvate carrier-deficient mice.
Topics: Animals; Anion Transport Proteins; Citric Acid Cycle; Diet, Ketogenic; Down-Regulation; Fasting; Hea | 2020 |
The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure.
Topics: Animals; Anion Transport Proteins; Cardiomegaly; Heart Failure; Heart-Assist Devices; Humans; Lactic | 2021 |
Remodeling of substrate consumption in the murine sTAC model of heart failure.
Topics: Acetyl Coenzyme A; Animals; Aorta; Citric Acid Cycle; Constriction; Disease Models, Animal; Energy M | 2019 |
Pyruvate restores β-adrenergic sensitivity of L-type Ca(2+) channels in failing rat heart: role of protein phosphatase.
Topics: Adrenergic beta-Agonists; Animals; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; H | 2013 |
Regulation of Kv4 channel expression in failing rat heart by the thioredoxin system.
Topics: Animals; Auranofin; Blotting, Western; Disease Models, Animal; Heart Failure; Isotretinoin; Kv Chann | 2008 |
Assessment of metabolic phenotypes in patients with non-ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy.
Topics: Adenosine Triphosphate; Adult; Aged; Amino Acids; Biomarkers; Blood Glucose; Cardiac Resynchronizati | 2010 |
Intracoronary pyruvate in cardiogenic shock as an adjunctive therapy to catecholamines and intra-aortic balloon pump shows beneficial effects on hemodynamics.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Cardiotonic Ag | 2011 |
Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart.
Topics: Adenosine Triphosphate; Animals; Bicarbonates; Carbon Isotopes; Cardiac Pacing, Artificial; Cardiac | 2013 |
Imaging the cardiac diet.
Topics: Animals; Cardiomyopathy, Dilated; Disease Models, Animal; Energy Metabolism; Glycolysis; Heart Failu | 2013 |
A study of the blood pyruvic acid level in patients with congestive heart failure.
Topics: Blood; Heart Failure; Humans; Pyruvates; Pyruvic Acid | 1954 |
[Significance of changes in blood lactic and pyruvic acid levels in cardiac decompensation].
Topics: Heart Failure; Lactic Acid; Pyruvates; Pyruvic Acid | 1956 |
[Significance of changes in blood lactic and pyruvic acid levels in cardiac decompensation].
Topics: Heart Failure; Lactic Acid; Pyruvates; Pyruvic Acid | 1956 |
[Significance of changes in blood lactic and pyruvic acid levels in cardiac decompensation].
Topics: Heart Failure; Lactic Acid; Pyruvates; Pyruvic Acid | 1956 |
[Significance of changes in blood lactic and pyruvic acid levels in cardiac decompensation].
Topics: Heart Failure; Lactic Acid; Pyruvates; Pyruvic Acid | 1956 |
[Pyruvic acid & cocarboxylase in cardiac decompensation].
Topics: Heart Failure; Pyruvates; Pyruvic Acid; Thiamine Pyrophosphate | 1957 |
[Behavior of serum pyruvic acid and alpha-ketoglutaric acid in congestive heart failure].
Topics: Heart Failure; Humans; Keto Acids; Ketoglutaric Acids; Ketones; Pyruvates; Pyruvic Acid | 1958 |
[Effect of cocarboxylase on blood pyruvic acid in cardiac decompensation and digitalis intoxication].
Topics: Cardiovascular Agents; Digitalis; Heart Failure; Pyruvates; Pyruvic Acid; Thiamine Pyrophosphate | 1958 |
[Pyruvic acid level in the blood and attempted use of cocarboxylase (berolase) in circulatory insufficiency].
Topics: Heart Failure; Pyruvates; Pyruvic Acid; Thiamine Pyrophosphate | 1961 |
[Contribution to the study of blood pyruvic acid in cardiac insufficiency].
Topics: Heart Failure; Pyruvates; Pyruvic Acid | 1963 |
[CONTENT OF GLYCOGEN, LACTIC AND PYRUVIC ACID IN THE MYOCARDIUM IN COMPENSATORY HYPERFUNCTION].
Topics: Animals; Carbohydrate Metabolism; Cardiomegaly; Glycogen; Heart Failure; Lactates; Metabolism; Myoca | 1963 |
Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiotonic Agents; Female; Heart Failure; Heart Rate; Hemodynamics; Hu | 2004 |
The force-frequency relationship in human heart failure: effect of pyruvate and isoproterenol.
Topics: Adrenergic beta-Agonists; Heart Failure; Heart Ventricles; Humans; Isoproterenol; Myocardial Contrac | 2005 |
[Congestive heart failure due to chronic alcoholism (author's transl)].
Topics: Beriberi; Cardiomyopathy, Alcoholic; Diagnosis, Differential; Electrocardiography; Heart Failure; Hu | 1982 |
[Status of several types of tissue metabolism at rest and during functional tests in patients in the initial stage of heart failure].
Topics: Acid-Base Equilibrium; Adult; Aged; Exercise Test; Female; Glycolysis; Heart Failure; Humans; Lactat | 1984 |
[Heart failure and its relationship with the type of hemodynamic shifts and function of the blood-saliva barrier in patients with acute myocardial infarct].
Topics: Female; Heart Failure; Hemodynamics; Humans; Male; Myocardial Infarction; Pyruvates; Pyruvic Acid; S | 1995 |
Renal circulation and cellular metabolism during left ventricular assisted circulation: comparison study of pulsatile and nonpulsatile assists.
Topics: Animals; beta 2-Microglobulin; Blood Pressure; Blood Urea Nitrogen; Creatinine; Disease Models, Anim | 1997 |
Altered K+ current of ventricular myocytes in rats with chronic myocardial infarction.
Topics: Animals; Cardiomegaly; Cells, Cultured; Coronary Vessels; Dichloroacetic Acid; Evoked Potentials; He | 1998 |
Potentiation of beta-adrenergic inotropic response by pyruvate in failing human myocardium.
Topics: Adrenergic beta-Agonists; Aged; Analysis of Variance; Calcium; Drug Synergism; Female; Heart Failure | 2002 |
Metabolic modulation: a means to mend a broken heart.
Topics: Calcium; Energy Metabolism; Glycolysis; Heart Failure; Humans; Models, Biological; Myocardial Contra | 2002 |
Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium.
Topics: Aequorin; Calcium; Cold Temperature; Culture Techniques; Dose-Response Relationship, Drug; Female; H | 2002 |
The role of SR Ca(2+)-content in blunted inotropic responsiveness of failing human myocardium.
Topics: Calcium; Heart Failure; Humans; Isoproterenol; Middle Aged; Myocardial Contraction; Myocardium; Pyru | 2002 |
Energy metabolism and mechanical function in perfused hearts of Syrian hamsters with dilated or hypertrophic cardiomyopathy.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Cardiomegaly; Carnitine; Coenzyme A; Coronary Circu | 1986 |